Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2014 Feb:50:114-21.
doi: 10.1016/j.exger.2013.12.001. Epub 2013 Dec 10.

Analysis of 27 vascular-related proteins reveals that NT-proBNP is a potential biomarker for Alzheimer's disease and mild cognitive impairment: a pilot-study

Josef Marksteiner  1 , Douglas Imarhiagbe  1 , Michaela Defrancesco  2 , Eberhard A Deisenhammer  2 , Georg Kemmler  3 , Christian Humpel  4
Affiliations
Multicenter Study

Analysis of 27 vascular-related proteins reveals that NT-proBNP is a potential biomarker for Alzheimer's disease and mild cognitive impairment: a pilot-study

Josef Marksteiner et al. Exp Gerontol. 2014 Feb.

Abstract

Alzheimer's disease (AD) is a severe neurodegenerative disease. Cerebrovascular changes often accompany AD-related pathology. Despite a considerable progress in the diagnostic accuracy of AD, no blood biomarkers have been established so far. The aim of the present study was to search for changes in plasma levels of 27 vascular-related proteins of healthy controls, patients with mild cognitive impairment (MCI) and AD. In a sample of 80 participants we showed that out of these 27 proteins, six proteins were slightly changed (up to 1.5×) in AD (alpha2-macroglobulin, apolipoprotein-A1, plasminogen activator inhibitor, RAGE, Tissue Inhibitors of Metalloproteinases-1 and Trombospondin-2) and one marker (serum amyloid A) was enhanced up to 6× but with a very high variance. However, N-terminal pro-brain natriuretic peptide (NT-proBNP) was significantly enhanced both in MCI and AD patients (1.9×). In a second analysis of a sample of 110 subjects including younger healthy controls, we confirmed that NT-proBNP has the potential to be a stable candidate protein for both diagnosis and AD disease progression.

Keywords: Alzheimer; Biomarker; Diagnosis; Mild cognitive impairment; Multiplex ELISA; NT-proBNP; Plasma.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Plasma NT-proBNP levels of young healthy controls (yCo), old controls (oCo), patients with mild cognitive impairment (MCI) and Alzheimer’s disease (AD); see Table 1. Statistical analysis was performed by one way ANOVA with a subsequent Fisher PLSD posthoc test. Values in parenthesis give the number of analyzed subjects.
Fig. 2
Fig. 2
Yearly conversion rates for plasma NT-proBNP levels from controls to mild cognitive impairment (CO to MCI) and MCI to Alzheimer’s disease (MCI to AD), as well as yearly changes in stable MCI (MCI–MCI) and stable AD (AD–AD). Values are given as mean ± SEM. The number in parenthesis gives the number of follow up patients. The groups were statistically compared against CO-MCI using one way ANOVA and a Fisher LSD posthoc test (*p < 0.05).
Fig. 3
Fig. 3
(A) ROC curve based on NT-proBNP plasma levels for MCI patients vs. controls. (B) ROC curve based on NT-proBNP plasma levels for patients with Alzheimer dementia vs. controls.
See this image and copyright information in PMC

References

    1. Bayes-Genis A. Plasma NT-proBNP: a new biomarker for diagnosis and monitoring of congestive heart failure (CHF) Timely Top. Med. Cardiovasc. Dis. 2006;10:E10. - PubMed
    1. Bionda C, Bergerot C, Ardail D, Rodriguez-Lafrasse C, Rousson R. Plasma BNP and NT-proBNP assays by automated immunoanalyzers: analytical and clinical study. Ann. Clin. Lab. Sci. 2006;36:299–306. - PubMed
    1. Blasko I, Lederer W, Oberbauer H, Walch T, Kemmler G, Hinterhuber H, Marksteiner J, Humpel C. Measurement of thirteen biological markers in CSF of patients with Alzheimer’s disease and other dementias. Dement. Geriatr. Cogn. Disord. 2006;21:9–15. - PubMed
    1. Blennow K. CSF biomarkers for Alzheimer’s disease: use in erarly diagnosis and evaluation of drug treatment. Expert. Rev. Mol. Diagn. 2005;5:661–672. - PubMed
    1. Borroni B, Volpi R, Martini G, Del Bono R, Archetti S, Colciaghi F, Akkawi NM, Di Luca M, Romanelli G, Caimi L, Padovani A. Peripheral blood abnormalities in Alzheimer disease: evidence for early endothelial dysfunction. Alzheimer Dis. Assoc. Disord. 2002;16:150–155. - PubMed

Publication types

MeSH terms